• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of ophthalmology >Intraocular pressure after intravitreal injection of triamcinolone acetonide.
【24h】

Intraocular pressure after intravitreal injection of triamcinolone acetonide.

机译：玻璃体内注射曲安奈德后的眼压。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or oedematous diseases. METHODS: The prospective consecutive non-comparative interventional case series study included 71 patients (75 eyes) with progressive exudative age related macular degeneration (n = 64 eyes) or diffuse diabetic macular oedema (n = 11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow up time was 6.86 (SD 2.52) months (range 3.1-14.47 months). RESULTS: IOP increased significantly (p<0.001) from 15.43 (3.26) mm Hg preoperatively to a mean maximum of 23.38 (8.37) mm Hg (range 13-64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about 2 months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalised about 6 months after the injection, without further medication. Eyes undergoing repeatedly intravitreal injections of triamcinolone acetonide showed only an elevation of IOP, if after the first injection a rise of IOP had occurred. CONCLUSIONS: After intravitreal injections of 25 mg of triamcinolone acetonide, an IOP elevation can develop in about 50% of eyes, starting about 1-2 months after the injection. In the vast majority, IOP can be normalised by topical medication, and returns to normal values without further medication about 6 months after the injection.
机译：目的：研究玻璃体腔注射曲安奈德作为眼内新血管或水肿性疾病的治疗后眼内压（IOP）的反应。方法：前瞻性连续非对照性干预病例系列研究包括71例玻璃体腔注射注射液的患者，其中75例患者为进行性渗出性年龄相关性黄斑变性（n = 64眼）或弥漫性糖尿病性黄斑水肿（n = 11只眼）。 25 mg曲安奈德。平均随访时间为6.86（SD 2.52）个月（范围3.1-14.47个月）。结果：眼压从术前的15.43（3.26）mm Hg显着增加（p <0.001）至术后的平均最大值23.38（8.37）mm Hg（范围13-64 mm Hg）。在39（52％）眼中观察到IOP升高到高于21 mm Hg的值。注射后约2个月，IOP升高。眼压升高的术前预测因素是年龄较小（p = 0.013）。它在统计学上与屈光不正，糖尿病的存在以及注射的适应症无关。除一只眼睛外，在所有眼睛中，局部用药可使眼压降低至正常范围，而无青光眼性视神经乳头改变。在眼压升高的眼中，注射后约6个月，眼压恢复正常，无需进一步药物治疗。如果在第一次注射后眼内压升高，则反复玻璃体内注射曲安奈德丙酮眼的眼睛仅显示眼压升高。结论：玻璃体内注射25 mg醋酸曲安奈德后，约有50％的眼睛会在注射后1-2个月开始出现IOP升高。在绝大多数情况下，可以通过局部用药使IOP正常化，并且在注射后约6个月无需进一步用药即可恢复到正常值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号